Regen Biopharma Inc (RGBP) 0.1400 $RGBP
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
PR Newswire - Wed Mar 23, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer (immunotherapy).
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
PR Newswire - Wed Feb 03, 7:30AM CST
Regen BioPharma, Inc. , (OTCBB: RGBP) and (PINK: RGBP) announced the filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 149.24 (+0.48), ATRA: 16.85 (+0.24), STML: 4.54 (-0.08), SNTA: 0.24 (-0.01), ATNM: 2.02 (-0.03), SNDX: 12.62 (-0.17), BLCM: 8.07 (+0.31), BPTH: 2.12 (+0.10), TEVA: 54.29 (+0.24), AGIO: 37.91 (+0.84), XLRN: 24.21 (-0.25), ARRY: 2.86 (+0.14)
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
PR Newswire - Tue Jan 26, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the Food and Drug Administration (FDA) of an application requesting Orphan Drug status for the use of HemaXellerate for the treatment of aplastic anemia.
Regen BioPharma signs formal cancer research collaboration agreement with National Institutes of Health
M2 - Thu Jan 21, 5:40AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) reported on Wednesday that it has entered into a formal cancer research collaboration agreement to jointly explore the biology of the NR2F6 protein with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
PR Newswire - Wed Jan 20, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), and Regen have entered into a formal research collaboration agreement to jointly explore the biology of the NR2F6 protein.
Regen BioPharma President Harry Lander Provides Open Letter to Shareholders on Company's Progress and Developments
PR Newswire - Wed Jan 13, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) provided the following update for its shareholders:
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 74.33 (+0.12)
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program with Dr. Santosh Kesari, Director of Neuro-oncology at John Wayne Cancer Institute
PR Newswire - Thu Nov 12, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the initiation of preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, Professor of Neurosciences, Director of Neuro-Oncology, and Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute. The studies will examine whether initial observations in mouse immune cells that NR2F6 silencing can be translated into human immune cells. If successful, these studies will serve as the basis for a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.
Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy
PR Newswire - Wed Nov 04, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced the filing of a patent application covering gene silencing of NR2F6 (a Protein Coding Gene) in various immune cell populations as a means of selectively activating the immune system to kill cancer cells. Researchers at Regen BioPharma have previously demonstrated that NR2F6 is an inhibitor of T cell development and activation[1]. In addition, a recent independent publication showed that immune cells from mice lacking NR2F6 are capable of killing prostate cancer cells[2]. The current patent application integrates the Company's knowledge of NR2F6 function, with clinically-applicable gene silencing techniques to create a patient-specific immune based therapy.
Regen BioPharma elects Harry Lander, PhD as president
M2 - Wed Oct 14, 4:15AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP)(OTC:RGBP) reported on Tuesday that it has elected Harry Lander, PhD as its new president.
Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President
PR Newswire - Tue Oct 13, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP, OTC: RGBP) today announced the appointment of Harry Lander, PhD as its new president. Dr. Lander will work closely with the Company's Chairman & CEO David Koos as Regen BioPharma prepares to take the next steps forward in small molecule and immuno-oncological therapeutics.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
Regen BioPharma, Inc. Submits IND Application to FDA on tCellVax, a Checkpoint Inhibitor for Cancer Therapy
PR Newswire - Wed Mar 23, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer (immunotherapy).
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
PR Newswire - Wed Feb 03, 7:30AM CST
Regen BioPharma, Inc. , (OTCBB: RGBP) and (PINK: RGBP) announced the filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.
Myelodysplastic Syndrome - Pipeline Review - Key Players & Comparative Analysis
M2 - Fri Jan 29, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fmbtgw/myelodysplastic) has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Acceleron Pharma, Inc. - Actinium Pharmaceuticals, Inc. - Advancell - Agios Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Apogenix GmbH - Arno Therapeutics, Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Atara Biotherapeutics, Inc. - Bellicum Pharmaceuticals, Inc. - Bio-Path Holdings, Inc. - BioLineRx, Ltd. - Pharma Mar, S.A. - Regen BioPharma, Inc. - Rich Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Sunesis Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Targazyme, Inc. - TetraLogic Pharmaceuticals - Teva Pharmaceutical Industries Limited - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. - (50 Others) Key Topics Covered: - Introduction - Myelodysplastic Syndrome - Overview - Therapeutics Development - Pipeline Products for Myelodysplastic Syndrome - Overview - Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis - Myelodysplastic Syndrome - Therapeutics under Development by Companies - Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Myelodysplastic Syndrome - Products under Development by Companies - Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes - Myelodysplastic Syndrome - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/fm...dysplastic
AMGN: 149.24 (+0.48), ATRA: 16.85 (+0.24), STML: 4.54 (-0.08), SNTA: 0.24 (-0.01), ATNM: 2.02 (-0.03), SNDX: 12.62 (-0.17), BLCM: 8.07 (+0.31), BPTH: 2.12 (+0.10), TEVA: 54.29 (+0.24), AGIO: 37.91 (+0.84), XLRN: 24.21 (-0.25), ARRY: 2.86 (+0.14)
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
PR Newswire - Tue Jan 26, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today submission to the Food and Drug Administration (FDA) of an application requesting Orphan Drug status for the use of HemaXellerate for the treatment of aplastic anemia.
Regen BioPharma signs formal cancer research collaboration agreement with National Institutes of Health
M2 - Thu Jan 21, 5:40AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) reported on Wednesday that it has entered into a formal cancer research collaboration agreement to jointly explore the biology of the NR2F6 protein with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
PR Newswire - Wed Jan 20, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), and Regen have entered into a formal research collaboration agreement to jointly explore the biology of the NR2F6 protein.
Regen BioPharma President Harry Lander Provides Open Letter to Shareholders on Company's Progress and Developments
PR Newswire - Wed Jan 13, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) provided the following update for its shareholders:
Regen BioPharma, Inc. Identifies Small Molecule Drug Candidates Targeting Its Proprietary Immune Checkpoint NR2F6
PR Newswire - Wed Dec 16, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today identification of a series of compounds that have been identified by biochemical testing which interact with the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating "a checkpoint inhibitor pill." Previously, the Company reported that the use of gene silencing of NR2F6 leads to induction of cancer stem cell differentiation, a process that renders malignant cancer cells benign.
Regen BioPharma passes US FDA's clearance to initiate clinical trial of HemaXellerate for treating Aplastic anemia
M2 - Wed Dec 16, 4:27AM CST
Biotechnology company Regen BioPharma (OTCBB:RGBP) stated on Tuesday that it plans to begin clinical trials of its Investigational New Drug (IND) of HemaXellerate in Aplastic anemia patients following the US Food and Drug Administration approval.
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate
PR Newswire - Tue Dec 15, 7:30AM CST
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today receipt of a communication from the U.S. Food and Drug Administration, allowing for initiation of clinical trials under its Investigational New Drug (IND) #15376.
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
PR Newswire - Tue Dec 01, 7:30AM CST
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team
Regen BioPharma Inc. Submits Response to FDA Questions on HemaXellerate Investigational New Drug Application
PR Newswire - Tue Nov 17, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) and (OTC Pink: RGBP) announced today the submission to the Food and Drug Administration (FDA) of data and responses to questions posed by the FDA with regards to HemaXellerate . The data package submitted contained the final preclinical toxicology experiments performed by Charles River Laboratories (NYSE: CRL) on behalf of Regen as well as details of the proposed clinical trial. Results of all studies demonstrated lack of toxicity and the Company is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate. HemXellerate is a cellular drug being developed by the Company designed to heal damaged bone marrow
CRL: 74.33 (+0.12)
Regen BioPharma Initiates NR2F6 T Cell Immunotherapy Preclinical Program with Dr. Santosh Kesari, Director of Neuro-oncology at John Wayne Cancer Institute
PR Newswire - Thu Nov 12, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced today the initiation of preclinical studies evaluating utilization of NR2F6 gene silencing as a means of stimulating the immune system in cancer patients with Dr. Santosh Kesari, Professor of Neurosciences, Director of Neuro-Oncology, and Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute. The studies will examine whether initial observations in mouse immune cells that NR2F6 silencing can be translated into human immune cells. If successful, these studies will serve as the basis for a new cancer immunotherapeutic drug candidate, which would be useful as a monotherapy or adjuvant with other cancer immune therapies.
Regen BioPharma Files Patent Application on Personalized Checkpoint Inhibitor Cancer Immunotherapy
PR Newswire - Wed Nov 04, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) and (OTC PINK: RGBP) announced the filing of a patent application covering gene silencing of NR2F6 (a Protein Coding Gene) in various immune cell populations as a means of selectively activating the immune system to kill cancer cells. Researchers at Regen BioPharma have previously demonstrated that NR2F6 is an inhibitor of T cell development and activation[1]. In addition, a recent independent publication showed that immune cells from mice lacking NR2F6 are capable of killing prostate cancer cells[2]. The current patent application integrates the Company's knowledge of NR2F6 function, with clinically-applicable gene silencing techniques to create a patient-specific immune based therapy.
Regen BioPharma elects Harry Lander, PhD as president
M2 - Wed Oct 14, 4:15AM CDT
Biotechnology company Regen BioPharma (OTCBB:RGBP)(OTC:RGBP) reported on Tuesday that it has elected Harry Lander, PhD as its new president.
Regen BioPharma Inc. Announces Appointment of Dr. Harry Lander as President
PR Newswire - Tue Oct 13, 7:30AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP, OTC: RGBP) today announced the appointment of Harry Lander, PhD as its new president. Dr. Lander will work closely with the Company's Chairman & CEO David Koos as Regen BioPharma prepares to take the next steps forward in small molecule and immuno-oncological therapeutics.
Regen BioPharma, Inc. Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers
PR Newswire - Tue Sep 29, 7:30AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) and (PINK: RGBP) reported today that an independent research laboratory has published that the cancer stem cell target gene NR2F6 is a key gene that controls anti-tumor immune surveillance. Regen BioPharma has several pieces of intellectual property related to NR2F6 including issued United States patent # 9,091,696, Modulation of NR2F6 and methods and uses thereof, that covers methods for identifying compounds that can modulate the function of NR2F6 in mammalian cells and several other applications with priority dates of 2008 including patent application # 14571262 that covers use of gene silenicing with short interfering nucleic acid (siNA) antisense, short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) for treatment for cancer.
Regen BioPharma, Inc. Director of Molecular Therapeutics to Speak at Stem Cell Conference Regarding Leukemia Research Being Conducted by the Company
PR Newswire - Mon Sep 28, 7:30AM CDT
Dr. Christine Ichim will present at Stem Cell Meeting on the Mesa
Regen BioPharma, Inc. Announces Positive Results from GLP Safety Study for HemaXellerate
PR Newswire - Fri Sep 25, 7:30AM CDT
Final Experiments Requested by FDA Completed
Entest BioMedical Updates Company Status and Future Plans
PR Newswire - Thu Sep 24, 9:30AM CDT
Entest BioMedical Inc. (PINK: ENTB) discussed the Company's current status and future plans.
